Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Bio-IT World July 14, 2004 Malorye A. Branca	The Pathways Promise By using the right tools, even a modest genomic data set can generate a good view into a particular biological pathway. Now, a range of new technologies is arising from academia as well as the commercial sector to meet this need.
Bio-IT World July 15, 2003	Millennium's PARIS Illuminates Pathways To address high-throughput-data challenges, Millennium Pharmaceuticals built the PAthway Resource and Information System, or PARIS -- a unique platform for combining knowledge from heterogeneous data sources in the construction of a pathway knowledgebase.
Bio-IT World November 12, 2002 Michael Goldman	A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico?
Bio-IT World October 10, 2003 Donna Mendrick	Microarrays That Make Drugs Safe Using DNA chips to discover potential toxicity in new drug compounds -- a key application of toxicogenomics -- can predict adverse effects before they occur, enabling safer clinical trials.
Bio-IT World November 2006 John Russell	Pathway Pioneers Innovative uses for pathway tools and exciting results from early users are sprouting like mushrooms after a spring rain -- albeit following a few harsh winters. And the usually risk-averse pharmaceutical industry has led in adopting pathway tools.
Information Today February 13, 2012	Elsevier Launches TargetInsights for Early Drug Discovery This online decision support tool enables scientists to search, monitor, and stay up-to-date with the latest biological insights reported in the scientific literature.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
Bio-IT World January 21, 2005	Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics.
Bio-IT World May 19, 2004 John Russell	Seeing the Forest and the Trees A tiny clearing in the fog of systems biology.
Bio-IT World Dec 2005/Jan 2006 John Russell	GeneGo's Pathway to Profits Steady growth in literature citations plus several major pharmaceutical deals and now a recent FDA commitment suggest pathway technology is gaining sufficient credibility and the furthest along commercially of all the systems biology niches.
CIO October 15, 2001 Stephanie Overby	Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age...
Bio-IT World August 2005 Maureen McDonough	Invitrogen Launches iPath Invitrogen has unveiled a free bioinformatics and systems biology research tool that can be found on the company's Web site. iPath allows users to click their way through 2,500 human genes, 171 signal transduction pathways, and 54 metabolic pathways.
BusinessWeek June 13, 2005 John Carey	The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications.
Bio-IT World September 16, 2004 Michael A. Greeley	Platforms for Pathways Investor interest in the next great blockbuster drug has been blistering hot; Phase II and Phase III compound companies are being funded at a near record-breaking pace now that the IPO window seems to be slightly open
Bio-IT World November 2006 Robert M. Frederickson	Managing Data on the Go GeneGo has created a suite of software and database products that aim to facilitate analysis of the biology behind different types of high-throughput experimentation and understand the effects of small molecule drug compounds in human tissues.
Bio-IT World February 2006 John Russell	Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems.
Bio-IT World March 10, 2003 Salvatore Salamone	Common Knowledge Two heads (or more) are better than one, except when they don't share information. That's where knowledge management comes in.
Bio-IT World March 8, 2005 John Russell	Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Bio-IT World June 17, 2004 John Russell	Systems Biology - Now Leaving on Track 1 Entelos, a leader in predictive biosimulation, partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. Michael French, chief business officer at Entelos, explains what powers the systems biology engine.
Bio-IT World April 15, 2003 Mark D. Uehling	Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.
Bio-IT World March 17, 2004	Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006.
Bio-IT World July 11, 2002 Malorye Branca	Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed.
Bio-IT World February 2006 Robert M. Frederickson	Experiments in Data Integration Teranode evolved from a group of University of Washington scientists and has rapidly become a leading developer of informatics software for bio-scientists.
Bio-IT World February 2007 John Russell	Ingenuity Launches IPA 5.0 In this pre-launch interview, Ingenuity CTO Ramon Feliciano discusses the major changes to Ingenuity Pathway Analysis that 5.0 will bring.
Bio-IT World March 10, 2003 Mark D. Uehling	Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together.
Bio-IT World September 2005 John Russell	BioSeek's MAP to Discovery Now, after roughly five years of platform development and building a database of assays, BioSeek seems poised for growth.
Bio-IT World March 17, 2004 Zachary Zimmerman	Testing Times for the FDA The FDA's pharmacogenomic guidance marks the beginning of a long process toward standardized tests.
Chemistry World May 17, 2006 Bea Perks	Biochemists Reveal Hidden Drug Effects Researchers have identified unexpected drug activities by probing biochemical pathways inside living cells.
Bio-IT World July 2005 Kevin Davies	Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference.
Bio-IT World October 10, 2003 Mark D. Uehling	Digging Into Digital Quarries Industrial-strength software is helping discover unexpected connections in the scientific literature.
Chemistry World March 15, 2010 Matt Wilkinson	An agile future Nick Roelofs, president of Agilent Technology's life sciences group, discusses how the company is planning to ride the waves of the economic recovery.
Bio-IT World September 2006 Nat Goodman	Getting a Handle on Systems Biology Systems biology is squarely an experimental field that eats, drinks, and breathes data. To do systems biology, you need an experimental system that is amenable to large-scale experimentation.
Bio-IT World July 14, 2004 Karen Hopkin	'Omics: The NextGeneration Researchers in industry and academia are cataloging collections of biochemical compounds (metabolomics) to determine how they respond when organisms are challenged by drugs, disease, or stress (metabonomics).
Bio-IT World June 2006 Kevin Davies	The Data Deluge: Deal or No Deal? Far from decrying the data glut, researchers should embrace the complexity of genomic and other sources of data, particularly for its predictive properties in the field of personalized medicine.
Bio-IT World December 15, 2004 Kevin Davies	Into the Valley of Innovation An interview with president and CEO Curt Carlson of research hothouse SRI International on new technology and accelerating drug development.
Pharmaceutical Executive February 1, 2013 William Looney	Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice.
Chemistry World June 27, 2012 Helen Bache	Schizophrenia: a disease of the brain? Scientists in China have unearthed further evidence that a malfunction of the immune system contributes to the development of schizophrenia.
Bio-IT World September 2006 John A. Wass	Integrating Knowledge The results of new mathematical routines have the potential to save pharmaceuticals millions of dollars in drug development. And yet the flow of successful drugs is dwindling. The problem goes beyond bureaucracy and lies in the complexity of the problem.
Bio-IT World February 2006 John Russell	Preventable Vioxx Problems? Pathway analysis tools might have identified Vioxx's problematic off-target activity much earlier. Wondering which modeling approach to use for your project?
Chemistry World March 30, 2009 Rebecca Trager	EPA announces new chemical toxicity plan New regulations mean the agency will now rely less on animal testing to assess toxicity and risk, focusing instead on using advanced tools from fields like genomics, molecular biology and computational sciences.
Chemistry World August 17, 2011 Josh Howgego	Worms Modified to Express Unnatural Amino Acids Unnatural amino acids have been expressed for the first time in complex multicellular organisms. Researchers hope this will open up new ways to track biochemical processes and disease pathways.
Bio-IT World May 2006 Kevin Davies	Interpreting Genes and Genomes From microarrays to sequencing technology, molecular diagnostics to the interactome, this year's Bio-IT World Conference showcased exciting advances in genome technology applications, in which software analysis and data management play critical roles.
Bio-IT World Jul/Aug 2006 John Russell	MathWorks Launches a 'Systems Biology' Tool The maker of the popular MATLAB programming environment recently launched a modeling product, SimBiology, aimed at systems biology and synthetic biology markets.
Pharmaceutical Executive September 1, 2012 Roy F. Waldron	Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector?
Chemistry World August 12, 2010 Andy Extance	Science controversy authors fight on Researchers asked to retract a Science paper describing a tool for analyzing metabolic networks have vowed to validate their much-criticised work.
Scientific American February 28, 2005 Gunjan Sinha	The Diet That Fits With the understanding that some diseases such as obesity are metabolic syndromes in which multiple biochemical pathways interact to cause complex symptoms, metabolic testing offers a way to gauge health over a lifetime.
Bio-IT World May 9, 2003 Michael Greeley	Mechanistic Models Investors are backing predictive modeling software that could speed drug development.
Chemistry World December 8, 2015 Colacci & Kleinstreuer	Rethinking risk assessment For the purposes of regulation, the onset of adverse effects is key to determining the level of exposure that presents an unreasonable risk for humans and ecosystems.
The Motley Fool June 29, 2011 Brian Orelli	Doubling Up in Biotech Lilly hits multiple targets with one drug.